John Magnani CSO and VP

Australia Database Directory connects you to the industry’s top professionals and even the general public from any country. Besides, our expert team takes great care in creating high-quality databases to help you reach your targets with ease. So, by utilizing our contacts, you can enjoy a significant return on investment in your business. In addition, our service is cost-effective, allowing you to invest only a small amount to see significant gains. Take advantage of our databases to increase customer involvement as well as drive sales in your business. Furthermore, do not hesitate to add our reliable and accurate data to your CRM system today.

John Magnani CSO and VP

Rate this post

contact name: John Magnani
contact job function details: cso
contact job function:

contact job title: CSO and VP

contact job seniority: c_suite

contact person city: Gaithersburg

contact person state: Maryland

contact person country: United States

contact person zip code:

business name: GlycoMimetics

business domain: glycomimetics.com

business facebook URL: https://www.facebook.com/pages/Glycomimetics/103091423089592

business linkedin: http://www.linkedin.com/company/819274

business twitter:

business website: http://www.glycomimetics.com

netherlands phone numbers list 1 million package

business angellist: http://angel.co/glycomimetics

business found year: 2003

business city: Rockville

business zip code:

business state: Maryland

business country: United States

business language: English

business employee: 33

ben maslona director of teacher personnel

business category: pharmaceuticals

business specialty: orphan drugs, carbohydrate chemistry, small molecule drugs, pharmaceuticals

business technology: css:_max-width,apache,mobile_friendly,wordpress_org,google_font_api,google_analytics,omniture_adobe,css:_device_width,asp_net,google_maps,nginx,recaptcha,new_relic

business description: GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases particularly where there is high unmet need. Based on that technology, we have developed a robust, diversified product pipeline.